Former Biogen CFO Michael McDonnell joins Moderna (NASDAQ: MRNA) board and Audit Committee
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Moderna, Inc. is adding experienced financial executive Michael McDonnell to its Board of Directors, effective July 8, 2026. He will serve as a Class II director until the 2029 annual meeting and join the Board’s Audit Committee.
McDonnell brings more than 35 years of financial leadership, including service as Chief Financial Officer of Biogen Inc. from August 2020 to February 2025 and prior CFO roles at multiple public companies. David Rubenstein is transitioning off the Audit Committee to the Nominating and Corporate Governance Committee. McDonnell will receive compensation under Moderna’s Amended and Restated Non-Employee Director Compensation Policy, and his appointment was also announced in a press release furnished as Exhibit 99.1.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board appointment effective date: July 8, 2026
Tenure as Biogen CFO: August 2020 – February 2025
Financial leadership experience: More than 35 years
+4 more
7 metrics
Board appointment effective date
July 8, 2026
Effective date of Michael McDonnell’s appointment to Moderna’s Board
Tenure as Biogen CFO
August 2020 – February 2025
Period McDonnell served as Executive Vice President and Chief Financial Officer of Biogen Inc.
Financial leadership experience
More than 35 years
McDonnell’s total financial leadership and public company experience
CFO experience duration
More than 24 years
Time spent serving as chief financial officer of public companies
Director class term end
2029 annual meeting
McDonnell will serve as a Class II director until this meeting or earlier departure
Press release exhibit number
Exhibit 99.1
Exhibit containing the press release announcing McDonnell’s appointment
Cover page data file exhibit
Exhibit 104
Cover Page Interactive Data File embedded in Inline XBRL document
Key Terms
Audit Committee, Nominating and Corporate Governance Committee, Amended and Restated Non-Employee Director Compensation Policy, Regulation FD Disclosure, +1 more
5 terms
Audit Committee financial
"Mr. McDonnell was also appointed to serve on the Audit Committee of the Board"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Nominating and Corporate Governance Committee financial
"appointed to serve on the Nominating and Corporate Governance Committee"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Amended and Restated Non-Employee Director Compensation Policy financial
"Pursuant to the Company’s Amended and Restated Non-Employee Director Compensation Policy"
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What board change did Moderna (MRNA) announce in this 8-K?
Moderna announced that Michael McDonnell has been appointed to its Board of Directors, effective July 8, 2026. He will serve as a Class II director and join the Audit Committee, strengthening the Board’s financial oversight and governance capabilities.
Who is Michael McDonnell, the new Moderna (MRNA) board member?
Michael McDonnell is a veteran financial executive with more than 35 years of leadership experience. He most recently served as Executive Vice President and Chief Financial Officer of Biogen Inc. from August 2020 through February 2025, and previously held CFO roles at several other public companies.
What committee roles are affected by Michael McDonnell’s appointment at Moderna (MRNA)?
Michael McDonnell will serve on Moderna’s Audit Committee following his Board appointment. At the same time, David Rubenstein ceased serving on the Audit Committee and was appointed to the Nominating and Corporate Governance Committee, adjusting committee responsibilities without changing overall board size.
How will Michael McDonnell be compensated as a Moderna (MRNA) director?
McDonnell will be eligible for non-employee director compensation under Moderna’s Amended and Restated Non-Employee Director Compensation Policy. He will receive an Initial Grant and a pro-rata portion of an Annual Grant, as described in the company’s 2026 proxy statement filed March 16, 2026.
How long will Michael McDonnell serve on Moderna’s (MRNA) Board?
McDonnell was appointed as a Class II director and will hold office until Moderna’s 2029 annual meeting of shareholders. His term could end earlier if he resigns, dies, or is removed, consistent with the company’s standard governance provisions for board service.
Did Moderna (MRNA) issue a press release about Michael McDonnell’s appointment?
Yes. On July 8, 2026, Moderna issued a press release announcing McDonnell’s appointment to the Board and Audit Committee. That press release is furnished as Exhibit 99.1 to the report and is treated as furnished, not filed, under Regulation FD.